BIOPHARMA CREDIT (Germany) Performance

B3P Stock   0.79  0.01  1.28%   
BIOPHARMA CREDIT has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.25, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BIOPHARMA CREDIT's returns are expected to increase less than the market. However, during the bear market, the loss of holding BIOPHARMA CREDIT is expected to be smaller as well. BIOPHARMA CREDIT now shows a risk of 1.34%. Please confirm BIOPHARMA CREDIT total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to decide if BIOPHARMA CREDIT will be following its price patterns.

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in BIOPHARMA CREDIT DL are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable basic indicators, BIOPHARMA CREDIT is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
  

BIOPHARMA CREDIT Relative Risk vs. Return Landscape

If you would invest  75.00  in BIOPHARMA CREDIT DL on September 9, 2025 and sell it today you would earn a total of  4.00  from holding BIOPHARMA CREDIT DL or generate 5.33% return on investment over 90 days. BIOPHARMA CREDIT DL is currently producing 0.0887% returns and takes up 1.3401% volatility of returns over 90 trading days. Put another way, 12% of traded stocks are less volatile than BIOPHARMA, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon BIOPHARMA CREDIT is expected to generate 1.93 times more return on investment than the market. However, the company is 1.93 times more volatile than its market benchmark. It trades about 0.07 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.11 per unit of risk.

BIOPHARMA CREDIT Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for BIOPHARMA CREDIT's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BIOPHARMA CREDIT DL, and traders can use it to determine the average amount a BIOPHARMA CREDIT's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0662

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskB3PHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 1.34
  actual daily
12
88% of assets are more volatile

Expected Return

 0.09
  actual daily
1
99% of assets have higher returns

Risk-Adjusted Return

 0.07
  actual daily
5
95% of assets perform better
Based on monthly moving average BIOPHARMA CREDIT is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BIOPHARMA CREDIT by adding it to a well-diversified portfolio.

About BIOPHARMA CREDIT Performance

By analyzing BIOPHARMA CREDIT's fundamental ratios, stakeholders can gain valuable insights into BIOPHARMA CREDIT's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BIOPHARMA CREDIT has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BIOPHARMA CREDIT has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.

Things to note about BIOPHARMA CREDIT performance evaluation

Checking the ongoing alerts about BIOPHARMA CREDIT for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BIOPHARMA CREDIT help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
BIOPHARMA CREDIT has some characteristics of a very speculative penny stock
Evaluating BIOPHARMA CREDIT's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate BIOPHARMA CREDIT's stock performance include:
  • Analyzing BIOPHARMA CREDIT's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BIOPHARMA CREDIT's stock is overvalued or undervalued compared to its peers.
  • Examining BIOPHARMA CREDIT's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating BIOPHARMA CREDIT's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BIOPHARMA CREDIT's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of BIOPHARMA CREDIT's stock. These opinions can provide insight into BIOPHARMA CREDIT's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating BIOPHARMA CREDIT's stock performance is not an exact science, and many factors can impact BIOPHARMA CREDIT's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for BIOPHARMA Stock analysis

When running BIOPHARMA CREDIT's price analysis, check to measure BIOPHARMA CREDIT's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BIOPHARMA CREDIT is operating at the current time. Most of BIOPHARMA CREDIT's value examination focuses on studying past and present price action to predict the probability of BIOPHARMA CREDIT's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BIOPHARMA CREDIT's price. Additionally, you may evaluate how the addition of BIOPHARMA CREDIT to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges